US drug agency approves drug for low sexual desire in womenBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h4522 (Published 20 August 2015) Cite this as: BMJ 2015;351:h4522
- Michael McCarthy
The US Food and Drug Administration (FDA) has approved the first drug for the treatment of women with low sexual desire. The drug, flibanserin, which is made by Sprout Pharmaceuticals, of Raleigh, North Carolina, will be marketed under the name Addyi.
“Today’s approval provides women distressed by their low sexual desire with an approved treatment option,” said Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research in a statement announcing the drug’s approval.
The approval comes after the agency was subject to an intense lobbying campaign by …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial